Tokuyama (4043) FY2026 Q3 Earnings Report

Quick View

Executive Summary

Operating income increased substantially despite a slight decline in revenue, resulting in earnings growth driven by margin improvement without revenue growth. Revenue was ¥251.52B (-0.7% YoY), operating income was ¥26.73B (+26.9%), ordinary income was ¥27.44B (+24.9%), and net income was ¥19.19B (¥16.83B in the previous year). The primary drivers of the earnings increase were improved raw material and fuel price differentials and strong performance in semiconductor-related products in the Electronic Advanced Materials segment, which offset the decline in overseas market conditions for PVC-related products.

Factors Affecting Earnings

【Revenue】Revenue was ¥251.52B, down 0.7% YoY. In the Chemicals segment, lower caustic soda exports and declining overseas PVC market conditions reduced revenue, while the Electronic Advanced Materials, Life Science, and Environmental Businesses increased revenue, limiting the overall decline. The increase in Life Science revenue was supported by the newly consolidated Tokuyama Life Science (TLS) Group.

【Profit and Loss】Operating income was ¥26.73B (+26.9% YoY), and the operating margin improved substantially to 10.6% from the previous year. Improved raw material and fuel price differentials of +¥10.3B and manufacturing cost improvements were positive factors, offsetting the ¥3.4B negative impact from declining overseas market conditions for PVC-related products. Ordinary income of ¥27.44B (+24.9%) broadly maintained the growth rate of operating income, while net income of ¥19.19B (¥16.83B in the previous year) grew at a slower rate than operating income due to the ¥8.68B burden from income taxes and other taxes. Special gains and losses included a ¥1.07B gain on the sale of investment securities and a ¥0.79B gain on the sale of fixed assets, against an impairment loss of ¥1.43B; the net contribution was limited and should be distinguished as a temporary factor. Overall, the results represent earnings growth despite a decline in revenue.

Segment Analysis

By revenue composition, Chemicals (¥79.18B) is the largest segment and the core business, while Electronic Advanced Materials makes a disproportionately large contribution to operating income. Operating income in Electronic Advanced Materials expanded sharply to ¥10.3B (+95% YoY), driven by the reversal of inventory valuation losses on polycrystalline silicon and increased sales volumes of IC chemicals and thermal management materials. Chemicals was nearly flat at ¥7.82B (-2%), while Cement increased substantially to ¥7.25B (+26%) due to sales price revisions and manufacturing cost improvements. Profitability differed significantly, with margins of 14.4% for Cement and 9.9% for Chemicals; the increased profitability of Electronic Advanced Materials was the primary driver of overall earnings growth.

Key Financial Indicators

Profitability: ROE was 6.6%, and the operating margin was 10.6% (improving from approximately 8.3% in the previous year).
Cash quality: Although OCF relative to net income is not directly disclosed, the increases in DSO and DIO indicate challenges in cash conversion.
Financial soundness: The equity ratio was 52.5% (based on XBRL disclosures), and the current ratio was 191.0%. Goodwill of ¥59.76B accounted for 20.5% of net assets.

Cash Flow Analysis

Cash and deposits were ¥49.47B, down from ¥59.44B in the previous year. The primary reason for the decline appears to have been M&A funding expenditures associated with the newly consolidated Tokuyama Life Science (TLS) Group; funds were arranged through ¥34.2B in additional long-term borrowings and ¥19.0B in additional commercial paper. In relation to capital expenditures, tangible fixed assets increased by ¥11.7B. Although liquidity itself remains at a sufficient level, cash generation should be monitored in light of the increasing trends in inventories and trade receivables.

Earnings Quality

The divergence between ordinary income of ¥27.44B and net income of ¥19.19B (consolidated net income) was primarily attributable to the ¥8.68B tax burden from income taxes and other taxes. Non-operating income of ¥5.63B represented 2.2% of revenue and did not reach the cautionary threshold of more than 5%. Special losses included an impairment loss of ¥1.43B, a temporary factor indicating that profitability in part of the business portfolio may have fallen below expectations. The net contribution from special gains and losses was small, and the increase in net income was primarily supported by improved profitability at the operating level.

Earnings Forecast and Guidance

The progress rates for the cumulative Q3 results against the full-year forecasts of revenue of ¥351.50B and operating income of ¥39.0B were 71.6% and 68.5%, respectively, slightly below the standard progress rate of 75%. The Company has revised its full-year operating income forecast downward, primarily due to declining chemical product prices and volumes, lower polycrystalline silicon sales volumes, and changes in the external environment for the diagnostics business. In contrast, the forecasts for Electronic Advanced Materials and Cement have been revised upward. In Q4, operating income of ¥12.27B and an operating margin of 12.3% will be required, exceeding the cumulative Q3 margin of 10.6%.

Shareholder Returns

The full-year dividend forecast is ¥120.00 per share (¥60.00 interim dividend and an assumed ¥60.00 year-end dividend). Based on the full-year net income forecast of ¥27.50B, the payout ratio is approximately 31.4%; given the levels of cash and deposits and retained earnings of ¥224.90B, concerns regarding dividend sustainability are limited. No share repurchases have been confirmed, and this payout ratio is based solely on dividends and excludes share repurchases.

Catalysts

【Short Term】The Q4 operating margin will be key to achieving the plan, while semiconductor demand trends for Electronic Advanced Materials and overseas market conditions for Chemicals will determine performance.

【Long Term】The briefing for the next medium-term management plan is scheduled for May 29, 2026, and the presentation of the medium- to long-term strategy will be closely watched. Realization of integration synergies with the TLS Group will also be a focus.

Industry Benchmark (For Reference; Compiled by the Company)

Profitability and Returns

Profitability exceeds the industry median and is at a level positioned toward the upper end of the industry.

Growth and Capital Efficiency

The revenue growth rate is below the industry median, making the Company distinctive within the industry because its earnings growth is attributable to improved profitability rather than growth.

※Source: Compiled by the Company

Risk Factors

1. PVC-related product market fluctuations: The Chemicals segment has been negatively affected by ¥3.4B due to declining overseas market conditions, and the full-year forecast anticipates lower revenue and earnings (revenue of ¥105.0B and operating income of ¥11.5B).

2. Increase in goodwill and intangible assets: Following the consolidation of the TLS Group, goodwill and intangible fixed assets increased sharply to ¥59.76B and ¥64.38B, respectively. Goodwill accounts for 20.5% of net assets, creating a risk of additional impairment if the profitability of the integrated business falls below plan.

3. Changes in the external environment for the diagnostics business: The Life Science segment is expected to post lower full-year earnings (operating income of ¥8.0B) due to changes in its product mix and increased amortization expenses for goodwill, and this is explicitly identified as a downside factor for earnings.

Key Takeaways from the Earnings Results

1. A key feature of this period’s results is an earnings structure driven by margin improvement without revenue growth: the operating margin improved substantially from the previous year while revenue declined slightly.

2. Operating income in the Electronic Advanced Materials segment expanded sharply by +95% YoY, indicating that the composition of segment earnings is gradually shifting from a Chemicals-centered structure toward Electronic Advanced Materials.

3. The full-year operating income forecast was revised downward. While factors contributing to lower earnings in Chemicals, polycrystalline silicon, and the diagnostics business were identified, the forecasts for Electronic Advanced Materials and Cement were revised upward, resulting in divergent trends across segments.

Theoretical Share Price (For Reference)

Sensitivity: ¥3,894–¥4,125 at ±1% for the cost of equity, and ¥4,003–¥4,012 at ±0.1 for ω.

Notes:

• Net assets as of the quarter-end are used (there is a timing difference from the full-year forecast).

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated using only publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI through an integrated analysis of XBRL earnings summary data and PDF earnings presentation materials. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting with professionals as necessary.

---End of Report---